AstraZeneca Gets Fast Imfinzi Review For SCLC
Will Compete With Roche’s Tecentriq
The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor
You may also be interested in...
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.
BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.